- Systematic review and meta-analysis of 165 randomised trials, including 19,124 adults receiving rocuronium or vecuronium for elective procedures.
- Sugammadex 2 mg/kg was compared with neostigmine 0.05 mg/kg for neuromuscular blockade reversal, though risk of bias across trials was generally unclear or high.
- Sugammadex shortened time to a train-of-four ratio above 0.9 by 10.49 minutes (95% CI -11.90 to -9.08; moderate GRADE) and lowered the risk of at least one adverse event (RR 0.72, 95% CI 0.61 to 0.84).
- The authors conclude sugammadex probably reverses blockade faster with fewer adverse events, including residual blockade, desaturation and bradycardia, though the evidence is rated moderate certainty.
Pharmacology
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Meta-analysis of 25 randomized controlled trials (3344 patients) comparing perioperative ketamine or esketamine with placebo or standard care for postoperative delirium.
- Ketamine (9 trials) and esketamine (16 trials) were compared with control, with subgroup analyses by dose, regimen, surgery type and timing of assessment.
- Both agents reduced postoperative delirium risk: ketamine RR 0.69 (95% CI 0.49-0.98, P = .04) and esketamine RR 0.58 (95% CI 0.36-0.95, P = .03).
- Dizziness risk rose (RR 1.45, 95% CI 1.14-1.84), and trial sequential analysis found the evidence inconclusive, so the authors call for large multicenter RCTs.
- Systematic review and meta-analysis of 14 reports of randomized trials (1,773 participants in the primary synthesis), all conducted in China, in adults undergoing cardiac surgery.
- Compared remimazolam-based with propofol-based general anesthesia for induction and maintenance.
- Remimazolam was associated with fewer trial-defined intraoperative hypotension (OR 0.31; 95% CI 0.20-0.47) and bradycardia events (OR 0.20; 95% CI 0.12-0.34), and shorter mechanical ventilation (MD -1.84 hours; 95% CI -2.34 to -1.35).
- Length of stay did not reach significance (MD -0.48 days; 95% CI -0.99 to 0.02; p = 0.06), major morbidity and mortality could not be pooled, and certainty was very low.
- Systematic review and meta-analysis of 12 randomised trials (n = 739) comparing remimazolam with sevoflurane for general anaesthesia maintenance or deep sedation.
- Remimazolam was compared with sevoflurane, with outcomes covering intraoperative haemodynamic stability and postoperative nausea and vomiting.
- Remimazolam reduced the risk of intraoperative hypotension versus sevoflurane, RR 0.38 (95% CI 0.25 to 0.57; P < 0.001).
- MAP and heart rate differences appeared only at specific time points, and the PONV reduction came from sensitivity analyses, not the primary analysis.
- Systematic review and meta-analysis of 11 randomised trials, including 3904 propofol-based and 3907 volatile-based patients undergoing curative cancer surgery.
- Compared propofol-based with volatile-based anaesthesia for adults having curative cancer surgery, with outcomes pooled using random-effects meta-analysis.
- No significant difference in overall survival (HR 1.05, 95%CI 0.94-1.17, p = 0.42) or recurrence-free survival (HR 1.06, 95%CI 0.95-1.19, p = 0.31).
- Mortality (RR 1.03, 95%CI 0.94-1.13) and recurrence (RR 0.92, 95%CI 0.76-1.12) showed no significant effect, though the authors call recurrence findings inconclusive on trial sequential analysis.
- Systematic review and meta-analysis of 15 RCTs including 3,274 older adults undergoing cardiac surgery.
- Perioperative dexmedetomidine was compared with placebo or alternative sedative or analgesic regimens for preventing postoperative delirium.
- Dexmedetomidine lowered postoperative delirium incidence (RR 0.70, 95% CI 0.56 to 0.86, p = 0.001; moderate certainty) but increased reported bradycardia (RR 2.08, 95% CI 1.31 to 3.31).
- The benefit appeared larger against active comparators than placebo or saline. The delirium duration reduction (MD -1.12 days) was low certainty with high heterogeneity.
- Meta-analysis with trial sequential analysis of RCTs in pediatric ENT surgery; ten trials were identified and six (414 patients) were pooled.
- Low-dose propofol given before extubation was compared with placebo for emergence agitation and related outcomes.
- Propofol reduced emergence agitation incidence (RR 0.57, 95% CI 0.42-0.78) and severity (MD -3.94, 95% CI -5.74 to -2.13).
- Time to extubation was slightly longer (MD 1.8 min, 95% CI 1.4-2.3), with no difference in recovery time or PACU length of stay.
- Systematic review and meta-analysis of 8 randomized trials with 916 children receiving sevoflurane-based general anesthesia, comparing esketamine with placebo.
- Esketamine was compared with placebo for preventing emergence delirium, with no significant differences across dosing, surgery type, route, or timing.
- Emergence delirium was reduced with esketamine (RR 0.35; 95% CI 0.26-0.48; p<0.0001), and postoperative pain scores were lower (SMD -0.58).
- Extubation was modestly prolonged by 1.72 minutes, and nausea and vomiting were reduced (RR 0.69); certainty was moderate for most outcomes, low for extubation time.
- This systematic review and meta-analysis pooled 21 studies (3 randomized trials) with 605 ketamine-treated CRPS patients, mostly at moderate to high risk of bias.
- Pain change was pooled from the earliest post-infusion assessment within 14 days, with scores rescaled to 0-10 against a pooled baseline of 7.4.
- The mean pain change was -3.6 (95% CI -4.7 to -2.5) within 14 days, and longer-term data up to 90 days suggested a gradual return toward baseline.
- Median responder rate was 65% (range 0-100%), but only 3 studies formally assessed predictors; sympathetically maintained pain (aOR 6.54) and obesity (aOR 8.75) had wide CIs.
- Meta-analysis of 35 randomized trials with 3831 patients comparing intraoperative low-dose IV esketamine (<1 mg/kg) with control for acute postoperative pain.
- Esketamine was compared with control, with outcomes including resting and movement pain, opioid use, rescue analgesia, and adverse events.
- Resting pain was lower at 4 h (MD -1.40, p<0.0001) through 48 h, movement pain at 12 to 48 h, and rescue analgesia was reduced (RR 0.52, p=0.0001).
- Authors describe a modest pain reduction with no significant adverse event difference, but note heterogeneity and limited evidence make the magnitude and consistency uncertain.
- Systematic review and network meta-analysis of 24 randomised trials including 2,130 adults undergoing surgery with single-injection peripheral nerve blocks.
- Compared eight pharmacological prophylactic strategies against control for preventing rebound pain after nerve block.
- Intravenous dexamethasone had the highest probability of reducing rebound pain incidence (SUCRA 0.91) and was judged definitely superior to control.
- Perineural dexamethasone and dexmedetomidine ranked highest for delaying rebound pain, while certainty of evidence ranged from very low to moderate.
- Systematic review and meta-analysis of five randomized controlled trials, including 646 adults undergoing brain surgery, with searches run through April 2025.
- Evaluated perioperative dexmedetomidine, given as a loading dose followed by a maintenance infusion, for preventing postoperative delirium.
- The pooled risk ratio was 0.47 (95% CI 0.35-0.63; p < 0.00001), a 53% reduction in delirium risk, with no heterogeneity (I2 = 0%).
- Subgroups showed similar effects across brain tumor and other cranial procedures, adverse events were comparable and mostly mild, and the authors call for multicenter trials.
- Systematic review and meta-analysis of 25 studies including 116,815 surgical patients, with 12 RCTs (n = 845) in the primary analysis.
- Compared perioperative intravenous methadone with other opioids, with respiratory depression defined as naloxone use, respiratory rate under 8/min, or SpO2 under 90%.
- Respiratory depression occurred in 7.7% of methadone patients versus 6.6% of controls, RR 1.22 (95% CI 0.76-1.95), which was not significant.
- The authors found no higher risk with methadone, but rated certainty of evidence as very low, and most data came from retrospective datasets.